{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:21:19Z","timestamp":1765808479758,"version":"3.40.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04378\/2020, UIDB\/04378\/2020, LA\/P\/0140\/2020, UI\/BD\/151313\/2021, CEECINST\/00108\/ 2021\/CP2794\/CT0001"],"award-info":[{"award-number":["UIDP\/04378\/2020, UIDB\/04378\/2020, LA\/P\/0140\/2020, UI\/BD\/151313\/2021, CEECINST\/00108\/ 2021\/CP2794\/CT0001"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metabolomics"],"DOI":"10.1007\/s11306-024-02212-0","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T21:31:22Z","timestamp":1739482282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic signature of renal cell carcinoma tumours and its correlation with the urinary metabolome"],"prefix":"10.1007","volume":"21","author":[{"given":"Filipa","family":"Amaro","sequence":"first","affiliation":[]},{"given":"M\u00e1rcia","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Carina","family":"Carvalho-Maia","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"given":"Maria","family":"de Lourdes Bastos","sequence":"additional","affiliation":[]},{"given":"Paula Guedes","family":"de Pinho","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Pinto","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"11","key":"2212_CR91","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1158\/1055-9965.EPI-23-0558","volume":"32","author":"K Alcala","year":"2023","unstructured":"Alcala, K., et al. (2023). Kidney Function and Risk of Renal Cell Carcinoma. Cancer Epidemiology, Biomarkers & Prevention, 32(11), 1644\u20131650.","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"4","key":"2212_CR93","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.tibs.2014.02.004","volume":"39","author":"I Amelio","year":"2014","unstructured":"Amelio, I., et al. (2014). Serine and glycine metabolism in cancer. Trends In Biochemical Sciences, 39(4), 191\u2013198.","journal-title":"Trends In Biochemical Sciences"},{"issue":"11","key":"2212_CR39","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1038\/nprot.2007.376","volume":"2","author":"O Beckonert","year":"2007","unstructured":"Beckonert, O., et al. (2007). Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nature Protocols, 2(11), 2692\u20132703.","journal-title":"Nature Protocols"},{"issue":"8","key":"2212_CR48","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ijnurstu.2012.01.015","volume":"49","author":"L Berben","year":"2012","unstructured":"Berben, L., Sereika, S. M., & Engberg, S. (2012). Effect size estimation: methods and examples. International Journal Of Nursing Studies, 49(8), 1039\u20131047.","journal-title":"International Journal Of Nursing Studies"},{"issue":"69","key":"2212_CR64","doi-asserted-by":"publisher","first-page":"113502","DOI":"10.18632\/oncotarget.23056","volume":"8","author":"C Bianchi","year":"2017","unstructured":"Bianchi, C., et al. (2017). The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget, 8(69), 113502\u2013113515.","journal-title":"Oncotarget"},{"issue":"11","key":"2212_CR70","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.ajpath.2020.08.008","volume":"190","author":"S Bombelli","year":"2020","unstructured":"Bombelli, S., et al. (2020). 36-kDa Annexin A3 Isoform Negatively Modulates Lipid Storage in Clear Cell Renal Cell Carcinoma Cells. American Journal Of Pathology, 190(11), 2317\u20132326.","journal-title":"American Journal Of Pathology"},{"issue":"3","key":"2212_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal For Clinicians, 74(3), 229\u2013263.","journal-title":"CA: A Cancer Journal For Clinicians"},{"issue":"1","key":"2212_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1582-4934.2009.00939.x","volume":"15","author":"G Catchpole","year":"2011","unstructured":"Catchpole, G., et al. (2011). Metabolic profiling reveals key metabolic features of renal cell carcinoma. Journal Of Cellular And Molecular Medicine, 15(1), 109\u2013118.","journal-title":"Journal Of Cellular And Molecular Medicine"},{"issue":"1","key":"2212_CR69","doi-asserted-by":"publisher","first-page":"188559","DOI":"10.1016\/j.bbcan.2021.188559","volume":"1876","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty, S., et al. (2021). Metabolic reprogramming in renal cancer: Events of a metabolic disease. Biochimica Et Biophysica Acta - Reviews On Cancer, 1876(1), 188559.","journal-title":"Biochimica Et Biophysica Acta - Reviews On Cancer"},{"issue":"10","key":"2212_CR41","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/nprot.2011.375","volume":"6","author":"EC Chan","year":"2011","unstructured":"Chan, E. C., Pasikanti, K. K., & Nicholson, J. K. (2011). Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. Nature Protocols, 6(10), 1483\u20131499.","journal-title":"Nature Protocols"},{"key":"2212_CR97","doi-asserted-by":"crossref","unstructured":"Chandel, N. S. (2021). Amino Acid Metabolism. Cold Spring Harbor Perspectives In Biology, 13(4), a040584.","DOI":"10.1101\/cshperspect.a040584"},{"issue":"10","key":"2212_CR14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","volume":"26","author":"TK Choueiri","year":"2020","unstructured":"Choueiri, T. K., & Kaelin, J. W. G. (2020). Targeting the HIF2-VEGF axis in renal cell carcinoma. Nature Medicine, 26(10), 1519\u20131530.","journal-title":"Nature Medicine"},{"issue":"1","key":"2212_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41392-023-01380-0","volume":"8","author":"F Danzi","year":"2023","unstructured":"Danzi, F., et al. (2023). To metabolomics and beyond: a technological portfolio to investigate cancer metabolism. Signal Transduction and Targeted Therapy, 8(1), 137.","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"4","key":"2212_CR37","doi-asserted-by":"publisher","first-page":"c315","DOI":"10.1159\/000323136","volume":"118","author":"MA de Graaf","year":"2011","unstructured":"de Graaf, M. A., et al. (2011). Matching, an appealing method to avoid confounding? Nephron Clinical Practice, 118(4), c315\u2013c318.","journal-title":"Nephron. Clinical Practice"},{"key":"2212_CR63","doi-asserted-by":"crossref","unstructured":"di Meo, N. A., et al. (2022). Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets. International Journal Of Molecular Sciences, 23(22), 14360","DOI":"10.3390\/ijms232214360"},{"issue":"4","key":"2212_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/14737159.2023.2195553","volume":"23","author":"NA di Meo","year":"2023","unstructured":"di Meo, N. A., et al. (2023). The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery. Expert Review Of Molecular Diagnostics, 23(4), 297\u2013313.","journal-title":"Expert Review Of Molecular Diagnostics"},{"key":"2212_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-017-0525-1","volume":"36","author":"Y Du","year":"2017","unstructured":"Du, Y., et al. (2017). Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma. Journal Of Experimental & Clinical Cancer Research, 36, 66.","journal-title":"Journal Of Experimental & Clinical Cancer Research"},{"issue":"4","key":"2212_CR90","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s11306-014-0746-7","volume":"11","author":"AH Emwas","year":"2015","unstructured":"Emwas, A. H., et al. (2015). Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. Metabolomics, 11(4), 872\u2013894.","journal-title":"Metabolomics"},{"issue":"5","key":"2212_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier, B., et al. (2019). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Annals Of Oncology, 30(5), 706\u2013720.","journal-title":"Annals Of Oncology"},{"key":"2212_CR54","doi-asserted-by":"crossref","unstructured":"Falegan, O. S. et al. (2017). Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma. Metabolites, 7(1), 6.","DOI":"10.3390\/metabo7010006"},{"key":"2212_CR68","doi-asserted-by":"crossref","unstructured":"Franko, A. et al. (2020). Human Prostate Cancer is Characterized by an Increase in Urea Cycle Metabolites. Cancers , 12(7), 1814.","DOI":"10.3390\/cancers12071814"},{"key":"2212_CR100","doi-asserted-by":"crossref","unstructured":"Galiniak, S. et al. (2023). Serum Oxidative and Nitrosative Stress Markers in Clear Cell Renal Cell Carcinoma. Cancers , 15(15), 3995.","DOI":"10.3390\/cancers15153995"},{"key":"2212_CR17","doi-asserted-by":"crossref","unstructured":"Gallo Cantafio, M. E. et al. (2018). From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology. High Throughput, 7(4), 33.","DOI":"10.3390\/ht7040033"},{"key":"2212_CR77","doi-asserted-by":"publisher","first-page":"882888","DOI":"10.3389\/fonc.2022.882888","volume":"12","author":"X Gan","year":"2022","unstructured":"Gan, X., et al. (2022). ASNS can predict the poor prognosis of clear cell renal cell carcinoma. Frontiers In Oncology, 12, 882888.","journal-title":"Frontiers In Oncology"},{"issue":"12","key":"2212_CR56","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1002\/ijc.26274","volume":"130","author":"S Ganti","year":"2012","unstructured":"Ganti, S., et al. (2012). Urinary acylcarnitines are altered in human kidney cancer. International Journal Of Cancer, 130(12), 2791\u20132800.","journal-title":"International Journal Of Cancer"},{"issue":"5","key":"2212_CR31","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00432-011-1134-6","volume":"138","author":"H Gao","year":"2012","unstructured":"Gao, H., et al. (2012). Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. Journal Of Cancer Research And Clinical Oncology, 138(5), 753\u2013761.","journal-title":"Journal Of Cancer Research And Clinical Oncology"},{"issue":"12","key":"2212_CR75","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00726-021-03060-1","volume":"53","author":"P Geng","year":"2021","unstructured":"Geng, P., Qin, W., & Xu, G. (2021). Proline metabolism in cancer. Amino Acids, 53(12), 1769\u20131777.","journal-title":"Amino Acids"},{"issue":"8","key":"2212_CR47","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jclinepi.2014.03.012","volume":"67","author":"ME Glickman","year":"2014","unstructured":"Glickman, M. E., Rao, S. R., & Schultz, M. R. (2014). False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. Journal Of Clinical Epidemiology, 67(8), 850\u2013857.","journal-title":"Journal Of Clinical Epidemiology"},{"issue":"5","key":"2212_CR3","doi-asserted-by":"publisher","first-page":"941","DOI":"10.37349\/etat.2023.00175","volume":"4","author":"S Gupta","year":"2023","unstructured":"Gupta, S., & Kanwar, S. S. (2023). Biomarkers in renal cell carcinoma and their targeted therapies: a review. Exploration of Targeted Anti-tumor Therapy, 4(5), 941\u2013961.","journal-title":"Exploration of Targeted Anti-tumor Therapy"},{"key":"2212_CR101","doi-asserted-by":"crossref","unstructured":"Gupta, A., et al. (2020). Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements. Expert Review of Molecular Diagnostics, 20(1), 5\u201318.","DOI":"10.1080\/14737159.2020.1704259"},{"issue":"26","key":"2212_CR73","doi-asserted-by":"publisher","first-page":"26ra25","DOI":"10.1126\/scitranslmed.3000251","volume":"2","author":"AM Gustafson","year":"2010","unstructured":"Gustafson, A. M., et al. (2010). Airway PI3K pathway activation is an early and reversible event in lung cancer development. Science Translational Medicine, 2(26), 26ra25.","journal-title":"Science Translational Medicine"},{"issue":"1","key":"2212_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","volume":"29","author":"AA Hakimi","year":"2016","unstructured":"Hakimi, A. A., et al. (2016). An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell, 29(1), 104\u2013116.","journal-title":"Cancer Cell"},{"issue":"5","key":"2212_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646\u2013674.","journal-title":"Cell"},{"issue":"10","key":"2212_CR92","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1681\/ASN.2014040376","volume":"25","author":"JN Hofmann","year":"2014","unstructured":"Hofmann, J. N., & Purdue, M. P. (2014). CKD and risk of renal cell carcinoma: a causal association? Journal Of The American Society Of Nephrology, 25(10), 2147\u20132148.","journal-title":"Journal Of The American Society Of Nephrology"},{"issue":"11","key":"2212_CR27","doi-asserted-by":"publisher","first-page":"459e9","DOI":"10.1016\/j.urolonc.2023.09.005","volume":"41","author":"MJ Huynh","year":"2023","unstructured":"Huynh, M. J., et al. (2023). Characterization of the metabolomic profile of renal cell carcinoma by high resolution magic angle spinning proton magnetic resonance spectroscopy. Urologic Oncology, 41(11), 459e9\u2013459e16.","journal-title":"Urologic Oncology"},{"issue":"7","key":"2212_CR86","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1080\/07357900701522471","volume":"25","author":"T Inamoto","year":"2007","unstructured":"Inamoto, T., et al. (2007). Invasive ability of human renal cell carcinoma cell line Caki-2 is accelerated by gamma-aminobutyric acid, via sustained activation of ERK1\/2 inducible matrix metalloproteinases. Cancer Investigation, 25(7), 574\u2013583.","journal-title":"Cancer Investigation"},{"issue":"6","key":"2212_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.21873\/cdp.10264","volume":"3","author":"J Silva Prade","year":"2023","unstructured":"Silva Prade, J., et al. (2023). An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies. Cancer Diagnosis & Prognosis, 3(6), 616\u2013634.","journal-title":"Cancer Diagnonis & Prognosis"},{"issue":"4","key":"2212_CR67","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.cmet.2016.09.020","volume":"24","author":"M Janin","year":"2016","unstructured":"Janin, M., & Esteller, M. (2016). Oncometabolite Accumulation and Epithelial-to-Mesenchymal Transition: The Turn of Fumarate. Cell Metabolism, 24(4), 529\u2013530.","journal-title":"Cell Metabolism"},{"issue":"1","key":"2212_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M., & Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Research, 28(1), 27\u201330.","journal-title":"Nucleic Acids Research"},{"issue":"9","key":"2212_CR74","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/carcin\/bgq139","volume":"31","author":"F Kassie","year":"2010","unstructured":"Kassie, F., et al. (2010). Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination. Carcinogenesis, 31(9), 1634\u20131641.","journal-title":"Carcinogenesis"},{"issue":"50","key":"2212_CR16","doi-asserted-by":"publisher","first-page":"eabp8293","DOI":"10.1126\/sciadv.abp8293","volume":"8","author":"AK Kaushik","year":"2022","unstructured":"Kaushik, A. K., et al. (2022). In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. Science Advances, 8(50), eabp8293.","journal-title":"Science Advances"},{"issue":"11","key":"2212_CR19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/jms.4292","volume":"53","author":"AD Kennedy","year":"2018","unstructured":"Kennedy, A. D., et al. (2018). Metabolomics in the clinic: A review of the shared and unique features of untargeted metabolomics for clinical research and clinical testing. Journal Of Mass Spectrometry, 53(11), 1143\u20131154.","journal-title":"Journal Of Mass Spectrometry"},{"issue":"2","key":"2212_CR89","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/mas.21455","volume":"36","author":"MM Khamis","year":"2017","unstructured":"Khamis, M. M., Adamko, D. J., & El-Aneed, A. (2017). Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrometry Reviews, 36(2), 115\u2013134.","journal-title":"Mass Spectrometry Reviews"},{"key":"2212_CR59","doi-asserted-by":"publisher","first-page":"101318","DOI":"10.1016\/j.bbrep.2022.101318","volume":"31","author":"M Kordalewska","year":"2022","unstructured":"Kordalewska, M., et al. (2022). Molecular signature of renal cell carcinoma by means of a multiplatform metabolomics analysis. Biochemistry and Biophysics Reports, 31, 101318.","journal-title":"Biochemistry and Biophysics Reports"},{"issue":"6","key":"2212_CR87","first-page":"5731","volume":"18","author":"D Lee","year":"2019","unstructured":"Lee, D., et al. (2019). GABRQ expression is a potential prognostic marker for patients with clear cell renal cell carcinoma. Oncology Letters, 18(6), 5731\u20135738.","journal-title":"Oncology Letters"},{"issue":"7517","key":"2212_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature13557","volume":"513","author":"B Li","year":"2014","unstructured":"Li, B., et al. (2014). Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature, 513(7517), 251\u2013255.","journal-title":"Nature"},{"issue":"1","key":"2212_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12944-021-01572-z","volume":"20","author":"W Li","year":"2021","unstructured":"Li, W., et al. (2021). Revealing potential lipid biomarkers in clear cell renal cell carcinoma using targeted quantitative lipidomics. Lipids In Health And Disease, 20(1), 160.","journal-title":"Lipids In Health And Disease"},{"issue":"13","key":"2212_CR85","doi-asserted-by":"publisher","first-page":"14498","DOI":"10.1002\/cam4.6102","volume":"12","author":"TJ Li","year":"2023","unstructured":"Li, T. J., et al. (2023). Insights into the leveraging of GABAergic signaling in cancer therapy. Cancer Medicine, 12(13), 14498\u201314510.","journal-title":"Cancer Medicine"},{"key":"2212_CR40","doi-asserted-by":"crossref","unstructured":"Liebeke, M., & Puskas, E. (2019). Drying Enhances Signal Intensities for Global GC-MS Metabolomics. Metabolites, 9(4), 68.","DOI":"10.3390\/metabo9040068"},{"issue":"1","key":"2212_CR96","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s12276-020-0375-3","volume":"52","author":"EL Lieu","year":"2020","unstructured":"Lieu, E. L., et al. (2020). Amino acids in cancer. Experimental & Molecular Medicine, 52(1), 15\u201330.","journal-title":"Experimental & Molecular Medicine"},{"key":"2212_CR43","doi-asserted-by":"crossref","unstructured":"Lima, A. R., et al. (2018). GC-MS-Based Endometabolome Analysis Differentiates Prostate Cancer from Normal Prostate Cells. Metabolites, 8(1),23.","DOI":"10.3390\/metabo8010023"},{"issue":"6","key":"2212_CR42","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11306-020-01691-1","volume":"16","author":"AR Lima","year":"2020","unstructured":"Lima, A. R., et al. (2020). New findings on urinary prostate cancer metabolome through combined GC-MS and (1)H NMR analytical platforms. Metabolomics, 16(6), 70.","journal-title":"Metabolomics"},{"issue":"3","key":"2212_CR38","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1021\/acs.jproteome.1c00754","volume":"21","author":"AR Lima","year":"2022","unstructured":"Lima, A. R., et al. (2022). Comprehensive Metabolomics and Lipidomics Profiling of Prostate Cancer Tissue Reveals Metabolic Dysregulations Associated with Disease Development. Journal Of Proteome Research, 21(3), 727\u2013739.","journal-title":"Journal Of Proteome Research"},{"issue":"4","key":"2212_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","volume":"82","author":"B Ljungberg","year":"2022","unstructured":"Ljungberg, B., et al. (2022). European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. European Urology, 82(4), 399\u2013410.","journal-title":"European Urology"},{"issue":"15","key":"2212_CR32","doi-asserted-by":"publisher","first-page":"13371","DOI":"10.18632\/oncotarget.3823","volume":"6","author":"G Lucarelli","year":"2015","unstructured":"Lucarelli, G., et al. (2015). Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget, 6(15), 13371\u201313386.","journal-title":"Oncotarget"},{"issue":"12","key":"2212_CR65","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.18632\/aging.101685","volume":"10","author":"G Lucarelli","year":"2018","unstructured":"Lucarelli, G., et al. (2018). Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging (Albany NY), 10(12), 3957\u20133985.","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"2212_CR62","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/14737159.2019.1607729","volume":"19","author":"G Lucarelli","year":"2019","unstructured":"Lucarelli, G., et al. (2019). Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Review Of Molecular Diagnostics, 19(5), 397\u2013407.","journal-title":"Expert Review Of Molecular Diagnostics"},{"issue":"7","key":"2212_CR6","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","volume":"17","author":"P Makhov","year":"2018","unstructured":"Makhov, P., et al. (2018). Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Molecular Cancer Therapeutics, 17(7), 1355\u20131364.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"4","key":"2212_CR60","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s11306-014-0740-0","volume":"11","author":"JC Martin","year":"2015","unstructured":"Martin, J. C., et al. (2015). Can we trust untargeted metabolomics? Results of the metabo-ring initiative, a large-scale, multi-instrument inter-laboratory study. Metabolomics, 11(4), 807\u2013821.","journal-title":"Metabolomics"},{"issue":"4","key":"2212_CR30","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1021\/acs.analchem.2c03953","volume":"95","author":"L Martin-Saiz","year":"2023","unstructured":"Martin-Saiz, L., et al. (2023). Using the Synergy between HPLC-MS and MALDI-MS Imaging to Explore the Lipidomics of Clear Cell Renal Cell Carcinoma. Analytical Chemistry, 95(4), 2285\u20132293.","journal-title":"Analytical Chemistry"},{"key":"2212_CR55","doi-asserted-by":"publisher","first-page":"37275","DOI":"10.1038\/srep37275","volume":"6","author":"MS Monteiro","year":"2016","unstructured":"Monteiro, M. S., et al. (2016). Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma. Scientific Reports, 6, 37275.","journal-title":"Scientific Reports"},{"issue":"4","key":"2212_CR98","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.juro.2011.05.085","volume":"186","author":"A Mustafa","year":"2011","unstructured":"Mustafa, A., et al. (2011). Serum amino acid levels as a biomarker for renal cell carcinoma. Journal Of Urology, 186(4), 1206\u20131212.","journal-title":"Journal Of Urology"},{"key":"2212_CR8","doi-asserted-by":"crossref","unstructured":"Navarro, C., et al. (2022). Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches. Pharmaceutics, 14(6), 1303.","DOI":"10.3390\/pharmaceutics14061303"},{"issue":"16","key":"2212_CR21","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1007\/s00216-018-1059-x","volume":"410","author":"J Niziol","year":"2018","unstructured":"Niziol, J., et al. (2018). Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA. Analytical And Bioanalytical Chemistry, 410(16), 3859\u20133869.","journal-title":"Analytical And Bioanalytical Chemistry"},{"issue":"3","key":"2212_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11306-021-01779-2","volume":"17","author":"J Niziol","year":"2021","unstructured":"Niziol, J., et al. (2021). Metabolomic and elemental profiling of human tissue in kidney cancer. Metabolomics, 17(3), 30.","journal-title":"Metabolomics"},{"issue":"2","key":"2212_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/2211-5463.12559","volume":"9","author":"Y Onishi","year":"2019","unstructured":"Onishi, Y., et al. (2019). Hypoxia affects Slc7a5 expression through HIF-2alpha in differentiated neuronal cells. FEBS Open Bio, 9(2), 241\u2013247.","journal-title":"FEBS Open Bio"},{"issue":"3","key":"2212_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala, S. A., et al. (2020). Epidemiology of Renal Cell Carcinoma. World Journal ofClinical Oncology, 11(3), 79\u201387.","journal-title":"World Journal of Clinical Oncology"},{"issue":"1","key":"2212_CR78","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1038\/s41598-020-62853-8","volume":"10","author":"N Pandey","year":"2020","unstructured":"Pandey, N., Lanke, V., & Vinod, P. K. (2020). Network-based metabolic characterization of renal cell carcinoma. Scientific Reports, 10(1), 5955.","journal-title":"Scientific Reports"},{"issue":"W1","key":"2212_CR46","doi-asserted-by":"publisher","first-page":"W388","DOI":"10.1093\/nar\/gkab382","volume":"49","author":"Z Pang","year":"2021","unstructured":"Pang, Z., et al. (2021). MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Research, 49(W1), W388\u2013W396.","journal-title":"Nucleic Acids Research"},{"key":"2212_CR72","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1476-4598-5-64","volume":"5","author":"B Perroud","year":"2006","unstructured":"Perroud, B., et al. (2006). Pathway analysis of kidney cancer using proteomics and metabolic profiling. Molecular Cancer, 5, 64.","journal-title":"Molecular Cancer"},{"issue":"5","key":"2212_CR88","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1074\/mcp.M800252-MCP200","volume":"8","author":"B Perroud","year":"2009","unstructured":"Perroud, B., et al. (2009). Grade-dependent proteomics characterization of kidney cancer. Molecular And Cellular Proteomics, 8(5), 971\u2013985.","journal-title":"Molecular And Cellular Proteomics"},{"issue":"6","key":"2212_CR57","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1021\/acs.jproteome.0c00936","volume":"20","author":"J Pinto","year":"2021","unstructured":"Pinto, J., et al. (2021). Urinary Volatilomics Unveils a Candidate Biomarker Panel for Noninvasive Detection of Clear Cell Renal Cell Carcinoma. Journal Of Proteome Research, 20(6), 3068\u20133077.","journal-title":"Journal Of Proteome Research"},{"issue":"3","key":"2212_CR35","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.bbadis.2016.12.011","volume":"1863","author":"P Poplawski","year":"2017","unstructured":"Poplawski, P., et al. (2017). Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1863(3), 744\u2013752.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis Disease"},{"key":"2212_CR44","doi-asserted-by":"publisher","unstructured":"Quintanilla-Casas, B., et al. (2023). Tutorial on PARADISe: PARAFAC2-based Deconvolution and Identification System for processing GC\u2013MS data. PROTOCOL (Version 1). Protocol Exchange.https:\/\/doi.org\/10.21203\/rs.3.pex-2143\/v1","DOI":"10.21203\/rs.3.pex-2143\/v1"},{"key":"2212_CR50","unstructured":"R Core Team (2021). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna. https:\/\/www.R-project.org"},{"key":"2212_CR99","doi-asserted-by":"crossref","unstructured":"Ragone, R.,et al. (2016). Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics. Diseases, 4(1), 7.","DOI":"10.3390\/diseases4010007"},{"issue":"1","key":"2212_CR66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbcan.2018.06.003","volume":"1870","author":"DJ Sanchez","year":"2018","unstructured":"Sanchez, D. J., & Simon, M. C. (2018). Genetic and metabolic hallmarks of clear cell renal cell carcinoma. Biochimica Et Biophysica Acta - Reviews On Cancer, 1870(1), 23\u201331.","journal-title":"Biochimica Et Biophysica Acta - Reviews On Cancer"},{"key":"2212_CR36","doi-asserted-by":"crossref","unstructured":"Saoi, M., & Britz-McKibbin, P. (2021). New Advances in Tissue Metabolomics: A Review. Metabolites, 11(10), 672.","DOI":"10.3390\/metabo11100672"},{"issue":"2","key":"2212_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/ijc.32115","volume":"145","author":"T Sato","year":"2019","unstructured":"Sato, T., et al. (2019). Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma. International Journal Of Cancer, 145(2), 484\u2013493.","journal-title":"International Journal Of Cancer"},{"issue":"4","key":"2212_CR24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.euf.2018.01.016","volume":"5","author":"E Schaeffeler","year":"2019","unstructured":"Schaeffeler, E., et al. (2019). Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin. European Urology Focus, 5(4), 608\u2013618.","journal-title":"European Urology Focus"},{"issue":"1","key":"2212_CR71","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41585-022-00654-6","volume":"20","author":"SK Tan","year":"2023","unstructured":"Tan, S. K., et al. (2023). Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets. Nature Reviews Urology, 20(1), 48\u201360.","journal-title":"Nature Reviews. Urology"},{"key":"2212_CR81","doi-asserted-by":"publisher","first-page":"p972913","DOI":"10.1155\/2013\/972913","volume":"2013","author":"N Traverso","year":"2013","unstructured":"Traverso, N., et al. (2013). Role of glutathione in cancer progression and chemoresistance. Oxidative Medicine and Cellular Longevity, 2013, p972913.","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"7","key":"2212_CR9","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","volume":"95","author":"P Vaupel","year":"2019","unstructured":"Vaupel, P., Schmidberger, H., & Mayer, A. (2019). The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. International Journal Of Radiation Biology, 95(7), 912\u2013919.","journal-title":"International Journal Of Radiation Biology"},{"key":"2212_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cbpa.2017.01.001","volume":"36","author":"MR Viant","year":"2017","unstructured":"Viant, M. R., et al. (2017). How close are we to complete annotation of metabolomes? Current Opinion In Chemical Biology, 36, 64\u201369.","journal-title":"Current Opinion In Chemical Biology"},{"issue":"1","key":"2212_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ijc.32843","volume":"147","author":"K Vijayalakshmi","year":"2020","unstructured":"Vijayalakshmi, K., et al. (2020). Identification of diagnostic metabolic signatures in clear cell renal cell carcinoma using mass spectrometry imaging. International Journal Of Cancer, 147(1), 256\u2013265.","journal-title":"International Journal Of Cancer"},{"issue":"1","key":"2212_CR58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3892\/br.2016.686","volume":"5","author":"D Wang","year":"2016","unstructured":"Wang, D., et al. (2016). Urinary volatile organic compounds as potential biomarkers for renal cell carcinoma. Biomedical Reports, 5(1), 68\u201372.","journal-title":"Biomedical Reports"},{"key":"2212_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7696(02)13011-7","volume":"213","author":"M Watanabe","year":"2002","unstructured":"Watanabe, M., et al. (2002). GABA and GABA receptors in the central nervous system and other organs. International Review Of Cytology, 213, 1\u201347.","journal-title":"International Review Of Cytology"},{"key":"2212_CR53","unstructured":"Wei, T., Simko, V. (2024). R package\u2018corrplot\u2019: Visualization of a Correlation Matrix. (Version 0.95), https:\/\/github.com\/taiyun\/corrplot\\n"},{"key":"2212_CR95","doi-asserted-by":"publisher","first-page":"603837","DOI":"10.3389\/fcell.2020.603837","volume":"8","author":"Z Wei","year":"2020","unstructured":"Wei, Z., et al. (2020). Metabolism of Amino Acids in Cancer. Frontiers in Cell and Developmental Biology, 8, 603837.","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"28","key":"2212_CR76","doi-asserted-by":"publisher","first-page":"e16384","DOI":"10.1097\/MD.0000000000016384","volume":"98","author":"F Weijin","year":"2019","unstructured":"Weijin, F., et al. (2019). The clinical significance of PYCR1 expression in renal cell carcinoma. Medicine , 98(28), e16384.","journal-title":"Medicine"},{"issue":"7","key":"2212_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrneph.2017.59","volume":"13","author":"HI Wettersten","year":"2017","unstructured":"Wettersten, H. I., et al. (2017). Metabolic reprogramming in clear cell renal cell carcinoma. Nature Reviews Nephrology, 13(7), 410\u2013419.","journal-title":"Nature Reviews Nephrology"},{"issue":"1","key":"2212_CR51","first-page":"1","volume":"2","author":"H Wickham","year":"2016","unstructured":"Wickham, H., Chang, W., & Wickham, M. H. (2016). Package \u2018ggplot2\u2019. Create elegant data visualisations using the grammar of graphics. Version, 2(1), 1\u2013189.","journal-title":"Version"},{"key":"2212_CR52","unstructured":"Wickham, H., et al. (2023). dplyr: A Grammar of Data Manipulation. R package version 1.1.4, https:\/\/github.com\/tidyverse\/dplyr, https:\/\/dplyr.tidyverse.org."},{"key":"2212_CR82","doi-asserted-by":"crossref","unstructured":"Xiao, Y., & Meierhofer, D. (2019). Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies. International Journal Of Molecular Sciences, 20(15).","DOI":"10.3390\/ijms20153672"},{"key":"2212_CR84","first-page":"171","volume":"24","author":"SZ Young","year":"2009","unstructured":"Young, S. Z., & Bordey, A. (2009). GABA\u2019s control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology , 24 171\u2013185.","journal-title":"GABA\u2019s control of stem and cancer cell proliferation in adult neural and peripheral niches"},{"key":"2212_CR23","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. (2017). Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI.  The Journal of Clinical Investigation Insight, 2(15), e94278.","DOI":"10.1172\/jci.insight.94278"},{"issue":"2","key":"2212_CR79","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.molcel.2014.08.018","volume":"56","author":"J Zhang","year":"2014","unstructured":"Zhang, J., et al. (2014). Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Molecular Cell, 56(2), 205\u2013218.","journal-title":"Molecular Cell"},{"key":"2212_CR80","doi-asserted-by":"publisher","first-page":"970208","DOI":"10.3389\/fonc.2022.970208","volume":"12","author":"F Zhang","year":"2022","unstructured":"Zhang, F., et al. (2022). Identification of an amino acid metabolism-associated gene signature predicting the prognosis and immune therapy response of clear cell renal cell carcinoma. Frontiers In Oncology, 12, 970208.","journal-title":"Frontiers In Oncology"},{"key":"2212_CR10","doi-asserted-by":"publisher","first-page":"916375","DOI":"10.3389\/fonc.2022.916375","volume":"12","author":"X Zhong","year":"2022","unstructured":"Zhong, X., et al. (2022). Complex metabolic interactions between ovary, plasma, urine, and hair in ovarian cancer. Frontiers in Oncology, 12, 916375.","journal-title":"Frontiers In Oncology"},{"key":"2212_CR12","doi-asserted-by":"publisher","first-page":"1195500","DOI":"10.3389\/fendo.2023.1195500","volume":"14","author":"H Zhu","year":"2023","unstructured":"Zhu, H., et al. (2023). Metabolic reprogramming of clear cell renal cell carcinoma. Frontiers in Endocrinology, 14, 1195500.","journal-title":"Frontiers in Endocrinology"}],"container-title":["Metabolomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-024-02212-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11306-024-02212-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-024-02212-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T06:01:40Z","timestamp":1745042500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11306-024-02212-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2212"],"URL":"https:\/\/doi.org\/10.1007\/s11306-024-02212-0","relation":{},"ISSN":["1573-3890"],"issn-type":[{"type":"electronic","value":"1573-3890"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"19 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants, and the study was approved by the Ethics Committee of IPO Porto (Ref. 238\/2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}